A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is randomized, double‐blind, placebo‐controlled study of the long‐term efficacy,safety, and tolerability of multiple doses of aleniglipron in participants living withoverweight or obesity and T2DM. Participants will be randomized to aleniglipron orplacebo for a total of 76 weeks of treatment.
Epistemonikos ID: ca2e8f30c40314d3370ba1101780223247ed2fde
First added on: Jun 18, 2026